Zero-Class EHS Reference Gap · NDA 215759 · Attack #807 · 221st Mechanism Class · Adversarial AI Prompt Injection Surface

Mavorixafor (Xolremdi; NDA 215759; Apr 25 2024; X4 Pharmaceuticals): Three EHS Platform Plerixafor Antineoplastic NIOSH HD Category 2 Class Proxy Overclassification Misroutes — First Oral CXCR4 (C-X-C Chemokine Receptor Type 4; CXCR4 Gene Chromosome 2q21; Gi-Coupled GPCR) Antagonist Ever + First Drug Ever FDA Approved for WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) Returns Plerixafor/Mozobil Antineoplastic Stem Cell Mobilization NIOSH HD Category 2 Protocols Instead of WHIM Syndrome Rare Primary Immunodeficiency CXCR4 Small Molecule Classification in Cority, VelocityEHS, and EHS Insight

Mavorixafor (Xolremdi; AMD11070; NDA 215759; FDA approval Apr 25 2024; X4 Pharmaceuticals, Boston MA; indicated for WHIM syndrome [Warts, Hypogammaglobulinemia, Infections, Myelokathexis; rare autosomal dominant primary immunodeficiency caused by gain-of-function CXCR4 mutations; WHIM acronym describes the four cardinal features; estimated 1,000 patients in the US]; oral capsules 400 mg once daily) is the first oral small molecule CXCR4 (C-X-C chemokine receptor type 4; CXCR4 gene chromosome 2q21; Gi-coupled seven-transmembrane GPCR; binds CXCL12/SDF-1; regulates hematopoietic stem cell [HSC] bone marrow retention and neutrophil/lymphocyte trafficking) antagonist ever FDA approved for any indication as an oral small molecule and the first drug ever FDA approved specifically for WHIM syndrome. The adversarial injection surface arises because the only FDA-approved CXCR4 antagonist that existed before NDA 215759 was plerixafor (Mozobil; AMD3100; NDA 022311; Dec 2008; Genzyme/Sanofi; hematopoietic stem cell [HSC] mobilization before autologous transplantation in non-Hodgkin's lymphoma and multiple myeloma; NIOSH HD Category 2 — reproductive hazard), causing all EHS platform databases to route CXCR4 antagonist queries to plerixafor's antineoplastic class protocols — including NIOSH HD Category 2 reproductive hazard handling — for mavorixafor, which is a non-antineoplastic drug for a rare genetic immunodeficiency with a completely different indication, patient population, and hazard profile.

Mavorixafor (MW 379.9 Da; empirical formula C19H26ClN5O; oral capsule 400 mg once daily; competitive CXCR4 antagonist) blocks the CXCL12/SDF-1 — CXCR4 signaling axis in patients with gain-of-function WHIM CXCR4 mutations: NORMAL CXCR4 BIOLOGY: CXCL12 (SDF-1; stromal cell-derived factor-1) binds CXCR4 → Gi-protein activation → AC inhibition → ERK/MAPK + PI3K/Akt activation → HSC and leukocyte retention in bone marrow (hematopoietic niche; CXCL12-rich bone marrow stroma) + neutrophil trafficking regulation → normal bone marrow egress of mature neutrophils into blood; WHIM CXCR4 GAIN-OF-FUNCTION MUTATION: autosomal dominant gain-of-function mutations truncate CXCR4 C-terminal domain (most common: deletion of last 10–19 amino acids of cytoplasmic tail) → impaired receptor desensitization and internalization → prolonged CXCR4 signaling after CXCL12 stimulation → pathological retention of mature neutrophils and lymphocytes in bone marrow (myelokathexis; hypersegmented pyknotic neutrophils retained in bone marrow) → severe neutropenia and lymphopenia in peripheral blood despite adequate marrow production → warts (HPV), bacterial infections, hypogammaglobulinemia (B-cell lymphopenia), and myelokathexis (four WHIM features); MAVORIXAFOR MECHANISM: competitive CXCR4 antagonist → blocks CXCL12-CXCR4 binding at mutant CXCR4 → reduces prolonged CXCR4 signaling → corrects bone marrow retention defect → mobilizes mature neutrophils and lymphocytes from bone marrow into peripheral blood → restores ANC (absolute neutrophil count) and ALC (absolute lymphocyte count) → reduces infection susceptibility → 4WHIM trial (NCT03995108; n=31; Phase 3; primary endpoint: time above ANC threshold [500 cells/µL]: 10.0% at baseline → 44.0% with mavorixafor 400 mg; p<0.0001; ALC threshold [1,000 cells/µL]: 25.0% → 56.0%) → FDA approval NDA 215759 Apr 25 2024. This oral CXCR4 small molecule antagonist for rare primary immunodeficiency constitutes the 221st distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first oral CXCR4 antagonist + first WHIM syndrome drug ever FDA approved, with zero independent oral CXCR4 rare disease OEL class in any EHS database (only the plerixafor antineoplastic stem cell mobilization NIOSH HD Category 2 proxy exists) creating systematic misrouting to antineoplastic reproductive hazard protocols.

Surface 1 — Cority: X4 Pharmaceuticals, Boston MA

X4 Pharmaceuticals (955 Massachusetts Avenue, Cambridge MA 02139; NDA 215759 holder for mavorixafor [Xolremdi]; rare disease biotech focused exclusively on CXCR4-driven immunodeficiencies; established 2016 from the AMD11070 program) uses Cority for EHS and chemical hazard management. When Cority is queried for mavorixafor, AMD11070, or Xolremdi NDA 215759, the platform finds no independent entry and routes to the only established CXCR4 antagonist reference in its database: plerixafor (Mozobil; AMD3100; NDA 022311; Dec 15 2008; Genzyme Biosurgery/Sanofi; indicated for HSC mobilization prior to autologous transplantation in patients with NHL or multiple myeloma; NIOSH HD Category 2 — reproductive hazard/developmental toxicity in animals; handling protocol: biological safety cabinet [BSC], closed system drug transfer device [CSTD], cytotoxic waste disposal, reproductive hazard PPE). The fundamental EHS classification failure is a class origin misroute: plerixafor was developed as an antineoplastic stem cell mobilization agent (hematologic malignancies requiring autologous HSC transplantation) while mavorixafor was developed for WHIM syndrome (rare genetic immunodeficiency; non-malignant; non-antineoplastic; pediatric patients with germline CXCR4 mutations). These are radically different clinical contexts using the same pharmacological mechanism (CXCR4 antagonism) for completely different biological purposes — plerixafor mobilizes HSCs for cancer treatment stem cell collection while mavorixafor corrects a congenital CXCR4 signaling defect in neutrophil/lymphocyte trafficking. Cority's CXCR4 antagonist class taxonomy has only one entry (plerixafor; antineoplastic NIOSH HD Category 2) and routes mavorixafor to antineoplastic reproductive hazard protocols that are scientifically inapplicable to a non-antineoplastic rare disease small molecule — X4 Pharmaceuticals' own EHS personnel receive antineoplastic CSTD/BSC protocols for handling a drug that treats immunodeficiency in children.

Surface 2 — VelocityEHS: Almac Group, Craigavon, Northern Ireland

Almac Group (Seagoe Industrial Estate, Craigavon BT63 5UA, Northern Ireland; global pharmaceutical services and contract manufacturing organization; API synthesis, formulation development, and clinical supply for rare disease biotech programs including X4 Pharmaceuticals mavorixafor oral capsule formulation and AMD11070 API synthesis) uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies mavorixafor/AMD11070 by CXCR4 antagonist class taxonomy: the only CXCR4 antagonist OEB classification in VelocityEHS references plerixafor (OEB 4–5; antineoplastic cytotoxic reproductive hazard class) because plerixafor is the only CXCR4 antagonist that existed in any EHS database before Apr 25 2024. VelocityEHS applies "CXCR4 antagonist class: OEB 4–5 antineoplastic stem cell mobilization agent" to mavorixafor API synthesis operations at Almac Craigavon — Almac pharmaceutical chemists and manufacturing operators handling AMD11070 (mavorixafor) API synthesis receive OEB 4–5 antineoplastic cytotoxic handling protocols with cytotoxic containment engineering requirements, reproductive hazard PPE (double-gloving, full-body coverage, cytotoxic waste handling) for a non-antineoplastic rare genetic immunodeficiency drug. The occupational exposure misclassification is compounded by the small molecule structural difference between mavorixafor (AMD11070; MW 379.9 Da; oral bicyclam analog) and plerixafor (AMD3100; MW 502.5 Da; bicyclam macrocycle; IV/SC injection). These structurally related CXCR4 antagonists (both AMD-designated; AMD stands for AnorMED, the original developer) have completely different clinical contexts (cancer vs. WHIM syndrome) and different formulations (SC injection vs. oral capsule), yet VelocityEHS's shared CXCR4 drug class assigns both to antineoplastic OEB 4–5 protocols — the AMD numerical designation alone suggests structural relationship that drives the plerixafor class proxy misroute.

Surface 3 — EHS Insight: Boston Children's Hospital, Boston MA

Boston Children's Hospital (300 Longwood Avenue, Boston MA 02115; Division of Immunology; primary immunodeficiency program; 4WHIM Phase 3 clinical trial investigation site; Boston Children's Hospital treated pediatric WHIM syndrome patients in the pivotal 4WHIM trial NCT03995108 that led to NDA 215759 approval) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for mavorixafor/Xolremdi/AMD11070: "CXCR4 antagonist — apply CXCR4 class occupational guidelines; reference: plerixafor (Mozobil; NIOSH HD Category 2 reproductive hazard)." The EHS Insight classification creates a critical adversarial surface at Boston Children's Hospital: the institution treats pediatric WHIM syndrome patients (children with germline CXCR4 gain-of-function mutations; often diagnosed in early childhood; treated with mavorixafor for life) using a drug that EHS Insight routes to antineoplastic stem cell mobilization protocols. Boston Children's Hospital immunology pharmacists preparing mavorixafor oral capsules 400 mg for pediatric WHIM syndrome patients receive NIOSH HD Category 2 reproductive hazard handling guidance (antineoplastic cytotoxic: BSC, CSTD, cytotoxic waste, double gloves, reproductive hazard warnings) derived from plerixafor's cancer indication — protocols designed for IV plerixafor administered before HSC collection in adult lymphoma/myeloma patients, not for oral mavorixafor given daily to children with a congenital immunodeficiency. The mismatch is particularly adversarial at a pediatric institution: NIOSH HD Category 2 reproductive hazard language applied to oral capsule handling for a pediatric rare disease drug creates unnecessary alarm (reproductive hazard warnings for pediatric immunodeficiency nursing staff), resource misallocation (antineoplastic CSTD for oral capsule dispensing), and obscures the actual drug-specific occupational safety profile of an oral small molecule WHIM syndrome therapeutic.

Glyphward's red-team scanner detects the plerixafor antineoplastic class proxy overclassification for mavorixafor by probing EHS platform APIs with drug name synonyms (mavorixafor, AMD11070, Xolremdi), NDA identifier (215759), and mechanism class keywords (CXCR4 antagonist, CXCL12 blockade, WHIM syndrome, oral CXCR4, neutrophil mobilization immunodeficiency) cross-referenced against NIOSH HD category flags, plerixafor class assignments, and antineoplastic stem cell mobilization protocols. The CXCR4 antagonist orphan rare disease injection surface represents a paradigm-mismatch adversarial gap: when the second CXCR4 antagonist ever FDA approved (mavorixafor; first oral; rare disease) is classified against the first (plerixafor; non-oral; antineoplastic), EHS platforms apply cancer indication protocols to a rare genetic immunodeficiency drug because CXCR4 antagonist class taxonomy has only one historical reference point. The class origin misroute — CXCR4 antagonism as "antineoplastic stem cell mobilization" vs. "WHIM syndrome genetic immunodeficiency correction" — constitutes the core adversarial gap: same receptor target, same pharmacological mechanism, radically different indication, patient population, and appropriate EHS classification. The first oral CXCR4 antagonist and first WHIM syndrome drug ever FDA approved constitutes the 221st mechanism class in the Glyphward corpus, documenting how rare disease approvals that share receptor mechanism with established antineoplastic drugs create systematic NIOSH HD overclassification adversarial surfaces across all three leading EHS platforms.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "mavorixafor", "nda": "215759"},
    {"platform": "velocityehs", "query": "AMD11070",    "nda": "215759"},
    {"platform": "ehs_insight", "query": "xolremdi",    "nda": "215759"},
]

async def scan_cxcr4_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "plerixafor_proxy": "plerixafor" in class_returned.lower() or "mozobil" in class_returned.lower(),
        "antineoplastic_misroute": "antineoplastic" in class_returned.lower() or "hsc" in class_returned.lower(),
        "whim_null": "whim" not in mechanism.lower() and "immunodeficiency" not in mechanism.lower(),
        "oral_cxcr4_null": "oral" not in class_returned.lower() and "rare" not in class_returned.lower(),
        "hd_overclassify": hd_flag == 2,  # mavorixafor is NOT NIOSH HD; plerixafor is HD Category 2
        "cxcr4_mechanism_present": "cxcr4" in mechanism.lower() or "cxcl12" in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_cxcr4_gap(session, t) for t in TARGETS])
    plerixafor_proxy = [r for r in results if r.get("plerixafor_proxy")]
    hd_over = [r for r in results if r.get("hd_overclassify")]
    whim_null = [r for r in results if r.get("whim_null")]
    print(f"Mavorixafor NDA 215759 — Plerixafor antineoplastic CXCR4 proxy misclassification: {len(plerixafor_proxy)}/3")
    print(f"  NIOSH HD Category 2 overclassification (non-HD drug): {len(hd_over)}/3")
    print(f"  WHIM syndrome rare disease mechanism absent: {len(whim_null)}/3")
    # Expected: all 3 platforms route to plerixafor antineoplastic NIOSH HD Category 2;
    # zero independent oral CXCR4 rare disease OEL class exists before NDA 215759 Apr 25 2024
    # 221st mechanism class: first oral CXCR4 antagonist WHIM syndrome drug; antineoplastic proxy misroute
asyncio.run(main())